Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.
Our knowledge of the pharmacogenetics of warfarin and clopidogrel continues to expand as we learn more about the individual genetic variations that contribute to the drugs' efficacy and toxicity. We aim to review the recent developments in the field and discuss the clinical implications for the treatment of ischemic stroke patients. Despite recent advances, there is still insufficient data to suggest that routine genetic testing improves outcomes in patients treated with warfarin or clopidogrel for prevention of stroke.
Department of Neurology, Harborview Medical Center, 325 9th Avenue, Box 359775, Seattle, WA 98104, USA. donohue@u.washington.edu
Megan M
MM
Donohue
David L
DL
Tirschwell
D000925:Anticoagulants / Q000627:therapeutic use*; D000077144:Clopidogrel; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D064420:Drug-Related Side Effects and Adverse Reactions; D055106:Genome-Wide Association Study; D006801:Humans; D010597:Pharmacogenetics; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D003577:Cytochrome P-450 Enzyme System; D000077144:Clopidogrel; D013988:Ticlopidine